{"filing":{"accession_number":"0001193125-26-349197","cik":"0001856725","ticker":"RANI","company_name":"Rani Therapeutics Holdings, Inc.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"rani-20260813.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1856725/000119312526349197/rani-20260813.htm"},"events":[{"id":27596,"run_id":25162,"accession_number":"0001193125-26-349197","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Item 2.02 discloses Rani Therapeutics' financial results for the three and six months ended June 30, 2026, including a press release furnished as Exhibit 99.1. The filing reports contract revenue of $1.7 million (Q2 2026 vs. $0 in Q2 2025), net loss of $8.4 million (Q2 2026 vs. $11.2 million in Q2 2025), and cash position of $53.4 million as of June 30, 2026. This is a standard quarterly earnings disclosure with consolidated financial statements and operational metrics material to investor assessment of the company's financial condition and progress.","company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29186,"accession_number":"0001193125-26-349197","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 2.02 discloses Rani Therapeutics' financial results for the three and six months ended June 30, 2026, including a press release furnished as Exhibit 99.1. The filing reports contract revenue of $1.7 million (Q2 2026 vs. $0 in Q2 2025), net loss of $8.4 million (Q2 2026 vs. $11.2 million in Q2 2025), and cash position of $53.4 million as of June 30, 2026. This is a standard quarterly earnings disclosure with consolidated financial statements and operational metrics material to investor assessment of the company's financial condition and progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:02:32.420488+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29186,"accession_number":"0001193125-26-349197","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 2.02 discloses Rani Therapeutics' financial results for the three and six months ended June 30, 2026, including a press release furnished as Exhibit 99.1. The filing reports contract revenue of $1.7 million (Q2 2026 vs. $0 in Q2 2025), net loss of $8.4 million (Q2 2026 vs. $11.2 million in Q2 2025), and cash position of $53.4 million as of June 30, 2026. This is a standard quarterly earnings disclosure with consolidated financial statements and operational metrics material to investor assessment of the company's financial condition and progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:02:32.420488+00:00","company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","filing_date":"2026-08-13"}]}